Synonyms: 8,11,14-Eicosatrienoic acid | DGLA | dihomo-gamma-linolenic acid | DS107 | Homo-gamma-linolenic acid
Compound class:
Synthetic organic
Comment: Diroleuton (dihomo-gamma-linolenic acid; DGLA) is a 20-carbon-chain fatty acid that is structurally very similar to arachadonic acid (AA). It competes with AA for binding to the substrate binding sites of the COX and lipoxygenase enzymes, and this effect reduces the production of inflammatory mediators (eicosanoids) from AA. DGLA can be converted to PGE1 and eicosapentaenoic acid (EPA), the latter being a precursor for the synthesis of series-3 prostaglandins, series-5 leukotrienes and series-3 thromboxanes.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
DS Biopharma have a research agent called DS107/DS107G (an oral formulation whose active pharmaceutical ingredient is DGLA) that has completed Phase 2 clinical trial in patients with atopic dermatitis (see NCT02211417). A second Phase 2 trial in atopic dermatitis, NCT02864498, is underway. DS107, and other novel therapies for atopic dermatitis are discussed by Vakharia and Silverberg (2017) [3]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02211417 | Oral DS107G in Moderate to Severe Atopic Dermatitis | Phase 2 Interventional | Dignity Sciences Ltd. | ||
NCT02864498 | Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients | Phase 2 Interventional | DS Biopharma |